X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Toraymyxin (Polymyxin B) is a small molecule drug candidate which is shown to inhibit bacterial respiration. It is being evaluated for the treatment of septic shock.
Lead Product(s): Polymyxin B Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Toraymyxin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
Through agreement, Baxter’s exclusive rights to commercialize Toraymyxin (polymyxin B), a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by Spectral’s Endotoxin Activity Assay.
Lead Product(s): Polymyxin B Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Toraymyxin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Baxter Healthcare Corporation
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Agreement February 21, 2024
Details:
PMX (Toraymyxin™ PMX-20R) is a polymyxin B extracorporeal direct hemoperfusion adsorption column which is highly effective in removing endotoxin which can cause sepsis, from the bloodstream.
Lead Product(s): Polymyxin B Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Toraymyxin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
The net proceeds are expected to be primarily used by the Company on its Phase III registration trial (Tigris) for its unique product for the treatment of patients with septic shock, Toraymyxin (polymyxin B), a therapeutic hemoperfusion device that removes endotoxin.
Lead Product(s): Polymyxin B Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Toraymyxin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Paradigm Capital
Deal Size: $3.7 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 10, 2023
Details:
Toraymyxin PMX 20R, is a Polymyxin B extracorporeal direct hemoperfusion adsorption column which is highly effective in removing endotoxin in the bloodstream.
Lead Product(s): Polymyxin B Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Toraymyxin PMX 20R
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Dialco Medical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
